Search Results - Wolff, Hans, Prof

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    Improving implementation of needle and syringe programmes to expand, scale up, and sustain evidence-based prevention interventions for HIV and hepatitis C in prisons

    Improving implementation of needle and syringe programmes to expand, scale up, and sustain evidence-based prevention interventions for HIV and hepatitis C in prisons by Kronfli, Nadine, MD, Bromberg, Daniel J, MSc, Wolff, Hans, Prof, Montanari, Linda, MSc, Vasyliev, Serheii, MD, Altice, Frederick L, Prof

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  2. 2
    Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial

    Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final res... by Rödel, Claus, Prof, Graeven, Ullrich, MD, Fietkau, Rainer, Prof, Hohenberger, Werner, Prof, Hothorn, Torsten, Prof, Arnold, Dirk, Prof, Hofheinz, Ralf-Dieter, Prof, Ghadimi, Michael, Prof, Wolff, Hendrik A, MD, Lang-Welzenbach, Marga, MSc, Raab, Hans-Rudolf, Prof, Wittekind, Christian, Prof, Ströbel, Philipp, Prof, Staib, Ludger, Prof, Wilhelm, Martin, Prof, Grabenbauer, Gerhard G, Prof, Hoffmanns, Hans, MD, Lindemann, Fritz, MD, Schlenska-Lange, Anke, MD, Folprecht, Gunnar, Prof, Sauer, Rolf, Prof, Liersch, Torsten, Prof

    Published in The lancet oncology
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

    Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with... by Al-Batran, Salah-Eddin, Prof, Hofheinz, Ralf D, Prof, Pauligk, Claudia, PhD, Kopp, Hans-Georg, MD, Haag, Georg Martin, MD, Luley, Kim Barbara, MD, Meiler, Johannes, MD, Homann, Nils, Prof, Lorenzen, Sylvie, MD, Schmalenberg, Harald, MD, Probst, Stephan, MD, Koenigsmann, Michael, Prof, Egger, Matthias, MD, Prasnikar, Nicole, MD, Caca, Karel, Prof, Trojan, Jörg, Prof, Martens, Uwe M, Prof, Block, Andreas, MD, Fischbach, Wolfgang, Prof, Mahlberg, Rolf, MD, Clemens, Michael, Prof, Illerhaus, Gerald, Prof, Zirlik, Katja, MD, Behringer, Dirk M, Prof, Schmiegel, Wolff, Prof, Pohl, Michael, MD, Heike, Michael, Prof, Ronellenfitsch, Ulrich, MD, Schuler, Martin, Prof, Bechstein, Wolf O, Prof, Königsrainer, Alfred, Prof, Gaiser, Timo, Prof, Schirmacher, Peter, Prof, Hozaeel, Wael, MD, Reichart, Alexander, MD, Goetze, Thorsten O, MD, Sievert, Mark, MD, Jäger, Elke, Prof, Mönig, Stefan, Prof, Tannapfel, Andrea, Prof

    Published in The lancet oncology
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: